Cas:2444-89-5 1-chloro-4-(4-chlorophenoxy)benzene manufacturer & supplier

We serve Chemical Name:1-chloro-4-(4-chlorophenoxy)benzene CAS:2444-89-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

1-chloro-4-(4-chlorophenoxy)benzene

Chemical Name:1-chloro-4-(4-chlorophenoxy)benzene
CAS.NO:2444-89-5
Synonyms:4,4′-Dichlorobiphenyl ether;4,4′-DICHLORODIPHENYL ETHER;p,p’-Dichlorodiphenyl oxide;4-Chlorophenyl ether
Molecular Formula:C12H8Cl2O
Molecular Weight:239.09700
HS Code:2903999090

Physical and Chemical Properties:
Melting point:30ºC
Boiling point:312ºC
Density:1.3g/cm3
Index of Refraction:1.594
PSA:9.23000
Exact Mass:237.99500
LogP:4.78570

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 4,4′-Dichlorobiphenyl ether chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-Chlorophenyl ether physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4,4′-DICHLORODIPHENYL ETHER Use and application,4,4′-Dichlorobiphenyl ether technical grade,usp/ep/jp grade.


Related News: The program will run alongside our ongoing Phase 3 INSPIRE Trial, and is expected to continue until commercial launch in such countries. 1-chloro-4-(4-chlorophenoxy)benzene manufacturer The agency said it was not yet ready to authorize Emergent BioSolutions Inc’s (EBS.N) plant for manufacturing the J&J vaccine. 1-chloro-4-(4-chlorophenoxy)benzene supplier He pointed out that Taiwan had 10 confirmed cases, versus more than 14,000 in mainland China. 1-chloro-4-(4-chlorophenoxy)benzene vendor The agency said it was not yet ready to authorize Emergent BioSolutions Inc’s (EBS.N) plant for manufacturing the J&J vaccine. 1-chloro-4-(4-chlorophenoxy)benzene factory GlaxoSmithKline (GSK) is at the bottom of the top 20 list with the lowest percentage R&D spend/annual revenue at 12%.��